Brain, Vol. 124, No. 11, 2177-2187,
November 2001
© 2001 Oxford University Press
Regulation of Schwann cell proliferation and apoptosis in PMP22-deficient mice and mouse models of Charcot–Marie–Tooth disease type 1A
.
Institute of Cell Biology, Department of Biology, Swiss Federal Institute of Technology, ETH-Hönggerberg, Zürich, Switzerland
Correspondence to:
Dr Ueli Suter, Institute of Cell Biology, ETH Hönggerberg CH-8093 Zürich E-mail: usuter{at}cell.biol.ethz.ch
Charcot–Marie–Tooth disease type 1A (CMT1A) is caused by an increased dosage of the peripheral myelin protein 22 (PMP22) gene or by point mutations affecting the same gene. Based on in vitro data, PMP22 might be involved, besides in its proven role in the regulation of myelination and myelin maintenance, in the control of Schwann cell proliferation and programmed cell death. In this report, we have used mice lacking PMP22 and mouse models for CMT1A to analyse Schwann cell proliferation and apoptosis in vivo during postnatal sciatic nerve development. Our results show that there is no significant change in the number of Schwann cells at postnatal day 1 in the analysed PMP22 mutants compared with the corresponding wild-type animals. Furthermore, the rate of proliferation also was not changed at this early developmental time point. In contrast, cell density and proliferation rates were increased, albeit with different kinetics, in all PMP22 mutants later in development. The increase in proliferation is paralleled by a higher number of apoptotic Schwann cells found in the nerves. Thus, increased Schwann cell proliferation and apoptosis, but only in later development and in adults, are hallmarks of PMP22 mutant mice, regardless of whether increased or decreased PMP22 gene dosage or point mutations affecting the PMP22 gene are responsible for the resulting demyelinating, dysmyelinating or amyelinating phenotypes.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. A. Amici, W. A. Dunn Jr, A. J. Murphy, N. C. Adams, N. W. Gale, D. M. Valenzuela, G. D. Yancopoulos, and L. Notterpek Peripheral Myelin Protein 22 Is in Complex with {alpha}6beta4 Integrin, and Its Absence Alters the Schwann Cell Basal Lamina J. Neurosci., January 25, 2006; 26(4): 1179 - 1189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Sahenk, H. N. Nagaraja, B. S. McCracken, W. M. King, M. L. Freimer, J. M. Cedarbaum, and J. R. Mendell NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients Neurology, September 13, 2005; 65(5): 681 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Koike, M Hirayama, M Yamamoto, H Ito, N Hattori, F Umehara, K Arimura, S Ikeda, Y Ando, M Nakazato, et al. Age associated axonal features in HNPP with 17p11.2 deletion in Japan J. Neurol. Neurosurg. Psychiatry, August 1, 2005; 76(8): 1109 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Devaux and S. S. Scherer Altered Ion Channels in an Animal Model of Charcot-Marie-Tooth Disease Type IA J. Neurosci., February 9, 2005; 25(6): 1470 - 1480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wadehra, L. Goodglick, and J. Braun The Tetraspan Protein EMP2 Modulates the Surface Expression of Caveolins and Glycosylphosphatidyl Inositol-linked Proteins Mol. Biol. Cell, May 1, 2004; 15(5): 2073 - 2083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. A. Street, C. L. Bennett, J. D. Goldy, A. J. Shirk, K. A. Kleopa, B. L Tempel, H. P. Lipe, S. S. Scherer, T. D. Bird, and P. F. Chance Mutation of a putative protein degradation gene LITAF/SIMPLE in Charcot-Marie-Tooth disease 1C Neurology, January 14, 2003; 60(1): 22 - 26. [Abstract] [Full Text] [PDF]
|
|